Cephalon to pay $130 million for stem-cell technology

Cephalon Inc is to pay $130 million upfront for access to stem-cell technology developed by Mesoblast Ltd of Australia as part of an alliance to develop and commercialise adult mesenchymal precursor stem cell therapeutics for disease.